Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanjing Hongdi Biotechnology Co., Ltd. (Hongdi Biotech) is a Chinese biotechnology company and the sole technical R&D center of Ruifu Pharmaceutical Technology (Guangzhou) Co., Ltd. Founded in 2019 and based in Nanjing, the company leverages its proprietary, globally patented carbocyclic locked nucleic acid (cLNA) technology platform to develop innovative small nucleic acid (oligonucleotide) therapeutics. Its lead candidate, RF2011, is a novel antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB) that entered Phase 1 clinical trials in late 2026. Hongdi Biotech aims to address significant unmet medical needs in infectious diseases and other therapeutic areas through its advanced oligonucleotide modification and delivery capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hongdi Biotechnology.